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Summary
QUESTIONS UNDER STUDY: We sought to identify
reasons for late human immunodeficiency virus (HIV) test-
ing or late presentation for care.
METHODS: A structured chart review was performed to
obtain data on test- and health-seeking behaviour of pa-
tients presenting late with CD4 cell counts below 350 cells/
µl or with acquired immunodeficiency syndrome (AIDS),
at the Zurich centre of the Swiss HIV Cohort Study
between January 2009 and December 2011. Logistic re-
gression analyses were used to compare demographic char-
acteristics of persons presenting late with not late
presenters.
RESULTS: Of 281 patients, 45% presented late, 48% were
chronically HIV-infected non-late presenters, and an ad-
ditional 7% fulfilled the <350 CD4 cells/µl criterion for
late presentation but a chart review revealed that lymph-
openia was caused by acute HIV infection. Among the late
presenters, 60% were first tested HIV positive in a private
practice. More than half of the tests (60%) were sugges-
ted by a physician, only 7% following a specific risk situ-
ation. The majority (88%) of patients entered medical care
within 1 month of testing HIV positive. Risk factors for
late presentation were older age (odds ratio [OR] for ≥50
vs <30 years: 3.16, p = 0.017), Asian versus Caucasian eth-
nicity (OR 3.5, p = 0.021). Compared with men who have
sex with men (MSM) without stable partnership, MSM in
a stable partnership appeared less likely to present late (OR
0.50, p = 0.034), whereas heterosexual men in a stable part-
nership had a 2.72–fold increased odds to present late (p =
0.049).
CONCLUSIONS: The frequency of late testing could be
reduced by promoting awareness, particularly among older
individuals and heterosexual men in stable partnerships.
Key words: HIV; late presentation; CD4 cell count; risk
factors; fraction of ambiguous nucleotides; acute HIV
infection
Introduction
Untreated infection with the human immunodeficiency vir-
us (HIV) progressively destroys the immune system lead-
ing to opportunistic illnesses and death. Since potent com-
bination antiretroviral therapy (cART) has been introduced,
morbidity and mortality of HIV-infected people has drastic-
ally improved [1–3]. However, a substantial proportion of
individuals are not aware of their HIV infection or do not
present for care and treatment until the disease is advanced
[4]. Late initiation of cART results in less favourable out-
comes [5–7] and is associated with increased medical costs
[8]. Furthermore, untreated people may contribute to the
spread of HIV for many years. In Europe, 33% to 42% and
49% to 54% of individuals were reported not to be dia-
gnosed with HIV until having CD4 cell count values below
200 cells/µl [9–12] and 350 cells/µl [4, 13, 14], respect-
ively, and up to 30% present with an acquired immunode-
ficiency syndrome (AIDS) defining illness [15]. Unfortu-
nately, different definitions for late presentation complicate
direct comparisons of the study findings [16]. A recent ini-
tiative resulted in a European consensus definition for late
presentation of HIV-infected persons: Individuals present-
ing for care with a CD4 cell count below 350 cells/µl or
with an AIDS-defining illness regardless of CD4 cell count
should be classified as late presenters [16]. Late presenta-
tion for care comprises two entities which are believed to
be quite different from each other in terms of risk factors
and interventions: (i.) late HIV testing, which reflects pa-
tients who are unaware of their HIV infection, and (ii.)
delayed presentation for care, including individuals who
are aware of their HIV infection but do not seek care right
away.
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The aim of this study was to apply this new consensus
definition to individuals entering care in a large HIV out-
patient clinic and to identify reasons for late HIV testing or
presentation for care through a detailed chart review. The
structured questionnaire developed during this study could
then serve for further prospective studies.
Methods
Patients and data collection
We selected patients from the University Hospital Zurich,
the largest centre of the Swiss HIV Cohort Study (SHCS).
The SHCS is a nationwide, multicentre cohort with con-
tinuous enrollment of HIV-infected individuals and semi-
annual study visits [17]. The responsible ethics committees
of each study centre approved this cohort study and written
informed consent was obtained from all individuals in-
cluded. The retrospective chart review was approved by
the Kantonale Ethikkomission Zürich (KEK-ZH-Nr.
2011–0455). For this study we included all individuals who
were enrolled in the SHCS from January 2009 to December
2011 at the HIV outpatient clinic of the Division of Infec-
tious Diseases and Hospital Epidemiology, University Hos-
pital Zurich with available CD4 cell count at enrollment.
Persons with CD4 cell counts below 350 cells/µl or with an
AIDS-defining illness were considered to be potential late
presenters. The other individuals served as a comparison
group. During the data collection it became clear that the
group of potential late presenters included a considerable
number of persons with acute HIV infection whose CD4
cell counts were below 350 cells/µl at the time of enroll-
ment. To ascertain that no individuals with acute HIV in-
fection were classified as late presenter or not late presenter
we matched data with the database of the Zurich Primary
HIV Infection Study (ZPHI; ClinicalTrials.gov identifier,
NCT00537966). This study includes all patients of the HIV
outpatient clinic of the Division of Infectious Diseases and
Hospital Epidemiology, University Hospital Zurich with
acute or recent HIV-1 infection, defined as (i.) acute retro-
viral syndrome and negative or indeterminate Westernblot
in the presence of a positive p24 antigen and/or detectable
plasma HIV-1 ribonucleic acid (RNA), (ii.) documented
seroconversion with or without symptoms within 90 days,
or (iii.) possible acute seroconversion syndrome (ARS),
positive Westernblot and detectable HIV-RNA, and a neg-
ative HIV-gp120 avidity, respectively detuned assay. We
thus analysed three groups of individuals: patients with an
acute or recent HIV infection, chronically infected not late
presenters, and late presenters. Demographic characterist-
ics and laboratory results were obtained from the SHCS
database.
The development of the questionnaire was partially based
on the questionnaire of the HIV Denmark initiative (cour-
tesy of Prof. Jens D. Lundgren, Copenhagen HIV Pro-
gramme) which has been extended and adapted as a result
of a pilot chart review of late presenting patients and feed-
back from the community. For a report on this project see
http://www.hiv-danmark.dk/fileadmin/user_upload/hiv-
danmark/pdf/Late_presenters-FINAL.pdf. As the question-
naire also had to be suitable for further studies with pro-
spective patient interviews, we included items which were
unlikely to be adequately documented in the clinical re-
cords, such as symptoms and structural factors at the time
of the first HIV test, fear and emotional response to HIV in-
fection, stigma and individual risk appraisal. Information
about the following items was included for further analysis:
(i.) setting in which the first positive HIV test was per-
formed, (ii.) reasons for the performance of the test, (iii.)
HIV-related symptoms before first HIV test, (iv.) number
of physicians seen because of the symptoms before first
positive HIV test, and (v.) duration between first positive
test and entering into medical care.
Ambiguity scores
Diagnostic procedures for newly diagnosed HIV-1 infec-
tions include a genotypic resistance test to detect poten-
tially transmitted drug resistance mutations, which have
to be considered when choosing the initial antiretroviral
treatment. As recently described by researchers from the
SHCS (www.shcs.ch) and the Zurich Primary HIV Infec-
tion Study (ZPHI; ClinicalTrials.gov identifier,
NCT00537966), the results from these resistance tests can
also be used to estimate the duration of the HIV infection
by determining the fraction of ambiguous nucleotides [18].
In bulk sequencing, ambiguous nucleotide calls arise when
different viral strains do not permit a precise determination
of the nucleotide at a specific position. The fraction of am-
biguous nucleotides thus reflects the polymorphism of the
HIV population within a patient and is an indirect measure
of the age of infection. To evaluate the suitability of am-
biguity scores for distinguishing the three patient groups,
we applied this method for all individuals who had results
from enrollment resistance tests available from the SHCS
resistance database.
Statistical analyses
We used EpiData V3.1 (http://www.epidata.dk, The
EpiData Association, Odense Denmark) for data collection
and Stata/SE 13.1 (StataCorp, College Station, Texas,
USA) for analyses. Comparisons across groups for categor-
ical variables were done with Chi-square tests, or Fish-
er's exact test if an expected cell count was less than five.
Continuous variables were analysed with Wilcoxon rank-
sum tests (two groups) or Kruskal-Wallis tests (three
groups). Factors associated with late presentation com-
pared with the combined groups of not late presentation
and acute HIV infection were further analysed with uni-
variable and multivariable logistic regression. Results of
the logistic regression were reported as odds ratios (ORs)
with 95% confidence intervals (CIs). We considered sex,
transmission categories (men who have sex with men
[MSM] and heterosexual intercourse), living in a stable
partnership, ethnicity, age (<30, 30–39, 40–49, 50+ years)
and educational level in the models. Transmission categor-
ies of injection drug use (IDU) and of other risks were ex-
cluded from the logistic regression because of small num-
bers. We allowed for interactions between sex, transmis-
sion category and type of partnership by creating a com-
bined variable with six levels: (i.) MSM without stable
partner, (ii.) male heterosexual without stable partner, (iii.)
female heterosexual without stable partner, (iv.) MSM with
Original article Swiss Med Wkly. 2014;144:w13961
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 2 of 8
stable partner, (v.) male heterosexual with stable partner,
and (vi.) female heterosexual with stable partner. Patients
were defined as living in stable partnerships if they
answered affirmatively on the question of whether they had
had a stable partnership for the preceding 6 months in an
interviewer-administered questionnaire at a regular SHCS
follow-up visit. A p-value <0.05 was considered statistic-
ally significant.
Results
Patient characteristics
From 01 January 2009 to 07 December 2011, 318 patients
were enrolled in the Zurich centre of the SHCS and had a
CD4 cell count available. The chart review revealed that
37 individuals did not qualify as late presenters, mostly be-
cause referral letters showed that they had been in care for
a longer period elsewhere prior to enrollment in the SHCS.
These people were excluded from the analysis since we had
no information about their initial CD4 cell counts. Of the
remaining 281 patients, 146 (52%) had a CD4 cell count
below 350 cells/µl and/or an AIDS-defining disease at re-
Table 1: Characteristics of the 281 individuals enrolled at the Zurich centre of the Swiss HIV Cohort Study between 01 January 2009 and 07 December 2011 and included
in this analysis. Late presenters (n = 125) and people with acute HIV infection (n = 21) had CD4 cell counts below 350 cells/µ or AIDS at enrollment. The remaining 135
persons represent the comparison group.
Not late Late Acute HIV infection Total p-value1 p-value2
Total individuals included 135 (48) 125 (45) 21 (7) 281 (100) – –
Sex:
Male
Female
112 (83)
23 (17)
97 (78)
28 (22)
21 (100)
0 (0)
230 (82)
51 (18)
0.027 0.348
Median age at HIV diagnosis
(IQR) [years]
34 (29–42) 38 (31–46) 34 (30–38) 35 (30–44) 0.010 0.004
Risk group:
Heterosexual
Male
Female
IDU
Male
Female
MSM
Other
30 (22)
9 (7)
21 (15)
4 (3)
3 (2)
1 (1)
98 (73)
3 (2)
49 (39)
25 (20)
24 (19)
4 (3)
2 (1)
2 (1)
67 (54)
5 (4)
4 (19)
4 (19)
0 (0)
0 (0)
0 (0)
0 (0)
17 (81)
0 (0)
83 (29)
38 (13)
45 (16)
8 (3)
5 (2)
3 (1)
182 (65)
8 (3)
0.0103 0.0073
Ethnicity:
Caucasian
African
Hispanic
Asian
109 (81)
9 (7)
10 (7)
7 (5)
90 (72)
15 (12)
6 (5)
14 (11)
14 (67)
4 (19)
3 (14)
0 (0)
213 (76)
28 (10)
19 (7)
21 (7)
0.052 0.102
Education:
School not completed
Mandatory school
Apprenticeship
Higher professional education
University degree
4 (3)
14 (10)
68 (51)
18 (13)
31 (23)
10 (8)
19 (15)
47 (37)
27 (22)
22 (18)
2 (9)
1 (5)
9 (43)
1 (5)
8 (38)
16 (6)
34 (12)
124 (44)
46 (16)
61 (22)
0.032 0.039
Stable partner:
Yes
No
84 (62)
51 (38)
74 (59)
51 (41)
13 (62)
8 (38)
171 (61)
110 (39)
0.912 0.703
First CD4 cell count:
Median (IQR) [cells/µl]
<100
100–199
200–349
350–499
500+
Missing
471 (376–580)
0 (0)
0 (0)
0 (0)
55 (40)
59 (44)
214 (16)
169 (55–261)
43 (34)
36 (29)
46 (37)
0 (0)
0 (0)
0 (0)
246 (193–278)
0 (0)
6 (29)
15 (71)
0 (0)
0 (0)
0 (0)
300 (152–447)
43 (15)
42 (15)
61 (22)
55 (20)
59 (21)
21 (7)
<0.001 <0.001
AIDS-defining illness at HIV
diagnosis
0 (0) 35 (28) 1 (5) 36 (11) <0.001 <0.001
First HIV RNA value5
Median (IQR) [log10 copies/ml]
4.5 (4.0–5.0) 5.0 (4.5–5.4) 5.7 (5.2–6.6) 4.8 (4.3–5.3) <0.001 <0.001
Known source of infection6 93 (70) 73 (60) 18 (86) 184 (67) 0.035 0.114
AIDS = acquired immunodeficiency syndrome; HIV = human immunodeficiency virus; lDU = injection drug use; IQR = interquartile range; MSM = men who have sex with
men; RNA = ribonucleic acid
Numbers in parentheses are percentages unless otherwise stated.
1 p-values for differences across all three groups from Fisher's exact tests for categorical variables and Kruskal-Wallis tests for continuous variables.
2 p-values for differences between late and non-late presenters from Fisher's exact tests for categorical variables and Wilcoxon rank-sum tests for continuous variables.
3 This p-value represents the comparison across all six groups.
4 CD4 values at HIV diagnosis not available for 21 patients in care elsewhere prior to enrollment.
5 HIV-1 RNA values from individuals not on antiretroviral therapy.
6 Based on 276 individuals with available information.
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gistration and were potential late presenters. However 21
(14%) of these potential late presenters were found to have
a low CD4 cell count during the acute phase of HIV in-
fection. We therefore analysed three groups consisting of
125/281 (45%) persons identified as true late presenters,
135/281 (48%) as not late presenters and 21/281 (7%) as
acutely infected individuals.
The characteristics of these 281 individuals are summar-
ised in table 1. Patients were primarily male (82%) and
Caucasian (76%). Late presentation was more frequent
among females than males (55% vs 42%, respectively), in
heterosexually infected individuals (59%) compared with
other risk groups (38%), and in the African and Asian
populations (54% and 67%, respectively) compared with
Caucasians (42%), but less common in Hispanics (32%).
The frequency of late presentation was low among indi-
viduals with a university degree or a completed appren-
ticeship (36% and 38%, respectively) and high among in-
dividuals who didn't finish school or had only completed
mandatory school (62% and 56%, respectively). However
Figure 1
Prevalence of symptoms prior to the HIV test among the 125 late
presenters. Error bars represent the 95% exact binomial confidence
intervals.
HIV = human immunodeficiency virus
Figure 2
Relationship between the year of infection and the fraction of
ambiguous nucleotides. The solid black line represents the mean
fraction as a function of the age of infection, where data points have
been binned according to the age of infection in years (n = 3,307
patients). (Figure adapted from [18] Roger D. Kouyos et al.:
Ambiguous Nucleotide Calls From Population-based Sequencing of
HIV-1 are a Marker for Viral Diversity and the Age of Infection,
Clinical Infectious Diseases, 2011, 52(4):532–539, by permission of
Oxford University Press.) The dashed horizontal lines depict the
mean fraction from the three groups of our study and the shaded
area represents the 95% confidence intervals. The three arrows
from the intersections of the curve with the horizontal lines point to
estimated durations of HIV infection of approximately 6, 3, and <1
years for the three groups.
HIV = human immunodeficiency virus
patients with higher professional education showed quite a
high percentage of late presentation (59%).
The 21 individuals with acute HIV infection selected in this
study were all male and predominantly MSM (81%). Note-
ably, 38% had a university degree compared with only 18%
among the late presenters. CD4 cell counts of persons with
acute HIV infection were substantially below 350 cells/
µl, but significantly higher than late presenters (246 [in-
terquartile range {IQR} 193–278] vs 169 [IQR 55–261]
cells/µl). Of the latter group, 43 and 36 individuals had
CD4 cell counts below 100 and from 100 to 199 cells/
µl, respectively, resulting in a total of 79/125 (63%) late
presenters with fewer than 200 cells/µl.
Circumstances of late presentation
The chart review of the 125 late presenters revealed that
75 (60%) had their first positive HIV test performed in a
private practice. Six patients (4.8%) had their first test at
an anonymous testing venue and three women (2.4%) were
diagnosed during pregnancy screening. A total of 26 (21%)
of the positive tests were performed in a hospital setting
and two (1.6%) were incidental findings in the context of
a blood donation. Only very few patients (6.4%) had their
first positive test performed outside of Switzerland. In 60%
of individuals the test was performed following a physi-
cian's suggestion, in 7.2% each because of a specific risk
situation and characteristic symptoms and in 6.4% because
the partner had been tested HIV positive.
Potentially HIV-related symptoms prior to the test were
present in 88 (70%) patients. The prevalence of the most
frequent symptoms is shown in figure 1. A total of 79 pa-
tients (63%) consulted a physician because of these symp-
toms. Before an HIV test was performed, a median of two
different physicians (IQR 1–3) were seen because of the
symptoms. However, once HIV was diagnosed, the ma-
jority (88%) of individuals entered medical care within 1
month, and only 4.8% waited for 1 year or more.
Ambiguous HIV-1 nucleotides to estimate the duration
of the HIV infection
Data about the fraction of ambiguous nucleotides was
available in 71 (53%) of the control group, in 65 (52%)
of true late presenters and 15 (71%) of patients with acute
HIV infection. Ambiguity scores were highest in late
presenters (0.014, 95% CI 0.012–0.17)), followed by not
late presenters (0.007, 95% CI 0.005–0.010) and lowest
for persons with acute HIV infection (0.003, 95% CI
0.000–0.006). All pairwise comparisons gave a p <0.01
(Wilcoxon rank-sum tests). As shown by the arrows in fig-
ure 2, these scores correspond to estimated durations of
HIV infection of approximately 6, 3, and <1 years for the
three groups.
Risk factors for late presentation
We analysed risk factors for late presentation in 265 in-
dividuals infected via homo- or heterosexual contacts, us-
ing the combined groups of not late presenters and acutely
HIV-infected persons as comparator. Results from univari-
able and multivariable logistic regression analyses are
shown in table 2. Compared with younger individuals (age
<30 years), persons above 50 years of age had 3.16–fold
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increased odds (95% CI 1.23‒8.17, p = 0.017), and Asian
people, as compared with Caucasians, had 3.5–fold in-
creased odds of presenting late (95% CI 1.21–10.14, p =
0.021). Compared with MSM without stable partnership,
MSM in a stable partnership were significantly less likely
to present late (OR 0.50, 95% CI 0.27–0.95, p = 0.034),
whereas heterosexual men in a stable partnership had
2.72–fold increased odds to present late (95% CI
1.004–7.37, p = 0.049).
Discussion
A total of 45% of the 281 newly enrolled HIV-infected
individuals in our clinic between 01 January 2009 and
07 December 2011 were late presenters according to the
European consensus definition, with a CD4 cell count
threshold of below 350 cells/µl or an AIDS-defining illness
[16]. This is considerably less than in the reports from Ger-
many, England and New Zealand with 49.5%, 49% and
50%, respectively [13, 14, 19]. COHERE, a large European
collaborative study involving over 80,000 patients from 35
countries recently even found a prevalence of 52% late
presenters in 2010/2011 [4]. Without a careful chart review,
we would have included 21 persons who presented with
acute HIV infection, resulting in 146 of 281 persons (52%).
Although the consensus definition advises repeating CD4
cell count determinations to exclude transient lymph-
openia, such confirmation is not mandatory and may ex-
plain some of the variations between reports with data
sources from different settings.
With routinely performed genotypic resistance tests we
demonstrated that the fraction of ambiguous nucleotides
[18] successfully discriminated the three groups in our
study and that it is a valid tool for further epidemiological
analyses.
The analysis of risk factors for late presentation revealed
that the HIV transmission categories, sex, and partnership
status, are not independent. We created a combined vari-
able of the above characteristics, which allowed us to dis-
sect differential effects. For example, MSM in a stable
partnership are much less likely to present late than het-
erosexual men in a stable partnership. This finding is in
concordance with a French study where, among non-mi-
grants, longstanding heterosexual couples had the highest
risk for late presentation [10]. Similarly, the association
of late presentation with older age has been described in
several other studies [10, 12, 13, 20, 21]. Furthermore, a
higher risk for late presentation in immigrants and ethnic
groups other than Caucasians has been shown previously
[9, 11, 12, 20]. Whereas Africans and Hispanics showed no
difference in late presentation compared to Caucasians in
our study, Asians were at significantly higher risk for late
presentation.
The chart review revealed that the majority of late present-
ing patients had symptoms and were diagnosed in private
practices. Only 7.2% of individuals specifically asked for
an HIV test because of the symptoms and a further 7.2%
because they were aware of a risk situation. The fact that in
our study almost 90% entered medical care within 1 month
after diagnosis shows that access to healthcare is excellent
in Switzerland. A study on delayed entry into HIV medic-
Table 2: Logistic regression analyses of cofactors associated with late presentation (n = 116) compared with the combined groups of not late presentation and acute HIV
infection (n = 149). Persons infected via injection drug use (n = 8) and other routes (n = 8) were omitted.
Univariable logistic regression Multivariable logistic regression
Factor OR (95% CI) p-value OR (95% CI) p-value
Interaction1 of sex, transmission category and partnership:
Without stable partner
MSM
Male heterosexual
Female heterosexual
With stable partner
MSM
Male heterosexual
Female heterosexual
Ethnicity:
Caucasian
Afroamerican
Hispanoamerican
Asian
Age group (years):
<30
30–39
40–49
50+
Education:
Apprenticeship
School not completed
Mandatory school
Higher professional education
University degree
1.00 (reference)
1.25 (0.34–4.65) 0.739
1.25 (0.37–4.21) 0.719
0.55 (0.30–1.02) 0.057
3.13 (1.23–7.92) 0.016
1.5 (0.67–3.38) 0.329
1.00 (reference)
1.64 (0.72–3.74) 0.235
0.54 (0.19–1.58) 0.262
2.82 (1.09–7.29) 0.032
1.00 (reference)
0.97 (0.51–1.83) 0.914
1.46 (0.73–2.92) 0.282
3.05 (1.26–7.4) 0.013
1.00 (reference)
2.62 (0.87–7.85) 0.086
2.47 (1.08–5.66) 0.032
2.29 (1.13–4.64) 0.021
1.04 (0.54–1.98) 0.912
1.00 (reference)
0.98 (0.25–3.95) 0.984
0.90 (0.23–3.53) 0.883
0.50 (0.27–0.95) 0.034
2.72 (1.004–7.37) 0.049
1.05 (0.40–2.74) 0.923
1.00 (reference)
1.33 (0.49–3.57) 0.576
0.72 (0.24–2.21) 0.566
3.5 (1.21–10.14) 0.021
1.00 (reference)
0.94 (0.47–1.86) 0.853
1.49 (0.71–3.12) 0.295
3.16 (1.23–8.17) 0.017
Not included2
CI = confidence interval; HIV = human immunodeficiency virus; MSM = men who have sex with men; OR = odds ratio
1 To allow for interactions between sex, transmission category and type of partnership we created a combined variable with six levels: (i.) MSM without stable partner
(reference), (ii.) male heterosexual without stable partner, (iii.) female heterosexual without stable partner, (iv.) MSM with stable partner, (v.) male heterosexual with stable
partner, (vi.) female heterosexual with stable partner.
2 Education was not included in the multivariable analysis because of collinearity with transmission category and sex: The education level of MSM was on average one
category higher.
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al care between 2000 and 2004 in the United States found
that 28% of newly diagnosed persons had a delay of more
than 3 months [22]. However, we also found that the HIV
risk perception of late presenters was suboptimal, as more
than half of them were tested after a physician's suggestion
and fewer than 10% because of a perceived risk situation.
Thus, late presentation in Switzerland seems to be driven
by late HIV testing as opposed to delayed presentation for
care after a positive HIV test.
The small number of people infected via injection drug use
in our study of newly enrolled patients since 2009 docu-
ments the success of the harm reduction programmes such
as needle exchange and opiate substitution programmes
since 1985 in Switzerland. The numbers of injection drug
users as well as people infected via other transmission
routes were too small to be included in the analysis of risk
factors.
The major limitation of the chart review was the large
variation in the level of detail in the medical histories.
Anamnestic information was often unstructured and did
not cover information about knowledge, individual risk ap-
praisal, fear, the role of stigma and other emotional reac-
tions to a potential HIV infection. We therefore recently
started a larger multicentre study in which late presenters
and not late presenters are interviewed prospectively re-
garding the circumstances of their HIV infection and dia-
gnosis. A further potential limitation is the fact that not all
HIV-infected individuals agreed to participate in the SHCS.
However, a recent survey showed that the SHCS includes
84% of all HIV-infected persons treated at the study centres
[23].
Our findings suggest that delayed entry into medical care
after an HIV diagnosis is rare. The frequency of late test-
ing, however, could be improved by promoting awareness
among older individuals and especially heterosexual men
in stable partnerships. Such strategies might complement
the current testing policies aimed at populations and per-
sons at risk.
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Figures (large format)
Figure 1
Prevalence of symptoms prior to the HIV test among the 125 late presenters. Error bars represent the 95% exact binomial confidence intervals.
HIV = human immunodeficiency virus
Figure 2
Relationship between the year of infection and the fraction of ambiguous nucleotides. The solid black line represents the mean fraction as a
function of the age of infection, where data points have been binned according to the age of infection in years (n = 3,307 patients). (Figure
adapted from [18] Roger D. Kouyos et al.: Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral
Diversity and the Age of Infection, Clinical Infectious Diseases, 2011, 52(4):532–539, by permission of Oxford University Press.) The dashed
horizontal lines depict the mean fraction from the three groups of our study and the shaded area represents the 95% confidence intervals. The
three arrows from the intersections of the curve with the horizontal lines point to estimated durations of HIV infection of approximately 6, 3, and
<1 years for the three groups.
HIV = human immunodeficiency virus
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